Current pharmacotherapies for atherosclerotic cardiovascular diseases

Jong Gil Park; Goo Taeg Oh

doi:10.1007/s12272-019-01116-1

Current pharmacotherapies for atherosclerotic cardiovascular diseases

Jong Gil Park
, Goo Taeg Oh

Department of Life Science

Research output: Contribution to journal › Review article › peer-review

18 Scopus citations

Abstract

Despite the introduction of statins for lowering LDL-C level, atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of death and morbidity worldwide. Combination therapies with statin and other lipid-lowering drugs, including ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, have unlocked additive benefits for treatment of ASCVD, but morbidity and mortality due to ASCVD remain high. New anti-inflammatory therapies have emerged for treatment and prevention of ASCVD to address these problems. Canakinumab neutralization of interleukin-1β (IL-1β) is the only verified therapy, and low-dose methotrexate holds promise due to its efficacy and safety for treatment of ASCVD. However, many agonistic and antagonistic candidates within inflammation pathways have failed to develop into useful drugs for ASCVD because of the complexity of the inflammatory process in atherosclerosis. In this review, we outline current and future pharmaceutical therapies for ASCVD in terms of lipid-modifying strategies and anti-inflammation treatments.

Original language	English
Pages (from-to)	206-223
Number of pages	18
Journal	Archives of Pharmacal Research
Volume	42
Issue number	3
DOIs	https://doi.org/10.1007/s12272-019-01116-1
State	Published - 1 Mar 2019

Bibliographical note

Funding Information:
Acknowledgements This study was supported by a National Research Foundation of Korea (NRF) Grant funded by the Korean government (Nos.2012R1A3A2026454, 2018R1C1B6005004) and by a Grant from the Korea Research Institute of Bioscience and Biotechnology.

Publisher Copyright:
© 2019, The Pharmaceutical Society of Korea.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Anti-inflammatory therapies
Atherosclerotic cardiovascular diseases (ASCVD)
Canakinumab
Ezetimibe
Lipid-lowering drugs
Methotrexate
PCSK9 inhibitor
Pharmaceutical therapies
Statin

Access to Document

10.1007/s12272-019-01116-1

Cite this

@article{230eb968160c41c19171b3734b6cb6fa,

title = "Current pharmacotherapies for atherosclerotic cardiovascular diseases",

abstract = "Despite the introduction of statins for lowering LDL-C level, atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of death and morbidity worldwide. Combination therapies with statin and other lipid-lowering drugs, including ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, have unlocked additive benefits for treatment of ASCVD, but morbidity and mortality due to ASCVD remain high. New anti-inflammatory therapies have emerged for treatment and prevention of ASCVD to address these problems. Canakinumab neutralization of interleukin-1β (IL-1β) is the only verified therapy, and low-dose methotrexate holds promise due to its efficacy and safety for treatment of ASCVD. However, many agonistic and antagonistic candidates within inflammation pathways have failed to develop into useful drugs for ASCVD because of the complexity of the inflammatory process in atherosclerosis. In this review, we outline current and future pharmaceutical therapies for ASCVD in terms of lipid-modifying strategies and anti-inflammation treatments.",

keywords = "Anti-inflammatory therapies, Atherosclerotic cardiovascular diseases (ASCVD), Canakinumab, Ezetimibe, Lipid-lowering drugs, Methotrexate, PCSK9 inhibitor, Pharmaceutical therapies, Statin",

author = "Park, \{Jong Gil\} and Oh, \{Goo Taeg\}",

note = "Funding Information: Acknowledgements This study was supported by a National Research Foundation of Korea (NRF) Grant funded by the Korean government (Nos.2012R1A3A2026454, 2018R1C1B6005004) and by a Grant from the Korea Research Institute of Bioscience and Biotechnology. Publisher Copyright: {\textcopyright} 2019, The Pharmaceutical Society of Korea.",

year = "2019",

month = mar,

day = "1",

doi = "10.1007/s12272-019-01116-1",

language = "English",

volume = "42",

pages = "206--223",

journal = "Archives of Pharmacal Research",

issn = "0253-6269",

publisher = "Pharmaceutical Society of Korea",

number = "3",

}

TY - JOUR

T1 - Current pharmacotherapies for atherosclerotic cardiovascular diseases

AU - Park, Jong Gil

AU - Oh, Goo Taeg

N1 - Funding Information: Acknowledgements This study was supported by a National Research Foundation of Korea (NRF) Grant funded by the Korean government (Nos.2012R1A3A2026454, 2018R1C1B6005004) and by a Grant from the Korea Research Institute of Bioscience and Biotechnology. Publisher Copyright: © 2019, The Pharmaceutical Society of Korea.

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Despite the introduction of statins for lowering LDL-C level, atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of death and morbidity worldwide. Combination therapies with statin and other lipid-lowering drugs, including ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, have unlocked additive benefits for treatment of ASCVD, but morbidity and mortality due to ASCVD remain high. New anti-inflammatory therapies have emerged for treatment and prevention of ASCVD to address these problems. Canakinumab neutralization of interleukin-1β (IL-1β) is the only verified therapy, and low-dose methotrexate holds promise due to its efficacy and safety for treatment of ASCVD. However, many agonistic and antagonistic candidates within inflammation pathways have failed to develop into useful drugs for ASCVD because of the complexity of the inflammatory process in atherosclerosis. In this review, we outline current and future pharmaceutical therapies for ASCVD in terms of lipid-modifying strategies and anti-inflammation treatments.

AB - Despite the introduction of statins for lowering LDL-C level, atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of death and morbidity worldwide. Combination therapies with statin and other lipid-lowering drugs, including ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, have unlocked additive benefits for treatment of ASCVD, but morbidity and mortality due to ASCVD remain high. New anti-inflammatory therapies have emerged for treatment and prevention of ASCVD to address these problems. Canakinumab neutralization of interleukin-1β (IL-1β) is the only verified therapy, and low-dose methotrexate holds promise due to its efficacy and safety for treatment of ASCVD. However, many agonistic and antagonistic candidates within inflammation pathways have failed to develop into useful drugs for ASCVD because of the complexity of the inflammatory process in atherosclerosis. In this review, we outline current and future pharmaceutical therapies for ASCVD in terms of lipid-modifying strategies and anti-inflammation treatments.

KW - Anti-inflammatory therapies

KW - Atherosclerotic cardiovascular diseases (ASCVD)

KW - Canakinumab

KW - Ezetimibe

KW - Lipid-lowering drugs

KW - Methotrexate

KW - PCSK9 inhibitor

KW - Pharmaceutical therapies

KW - Statin

UR - https://www.scopus.com/pages/publications/85061188651

U2 - 10.1007/s12272-019-01116-1

DO - 10.1007/s12272-019-01116-1

M3 - Review article

C2 - 30725249

AN - SCOPUS:85061188651

SN - 0253-6269

VL - 42

SP - 206

EP - 223

JO - Archives of Pharmacal Research

JF - Archives of Pharmacal Research

IS - 3

ER -

Current pharmacotherapies for atherosclerotic cardiovascular diseases

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this